Most Read Articles
Pearl Toh, 3 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 3 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.

Sleep-disordered breathing may be a risk factor for glucose elevations in GDM

02 Aug 2020

Among women with gestational diabetes mellitus (GDM), increased severity of sleep-disordered breathing (SDB) is associated with poor glycaemic control during the night and early morning, a study has found.

Sixty-five women with GDM (mean age, 35 years; 31 percent on insulin) underwent sleep recordings and 72-hour continuous glucose monitoring (CGM). Their mean bedtime was about 10:30 pm, while mean waking time was around 7:00 am. On average, most participants were overweight or mildly obese, and the mean body mass index (BMI) was 33 kg/m2.

The mean time difference between the CGM and the sleep study was 6 days. Sixty-six percent of the population had an apnoea-hypopnea index (AHI) >10. The majority of respiratory events were related to arousals rather than oxygen desaturation. The mean REM-AHI was 30 events/hour and was greater than the non-REM-AHI (13 events/hour).

Linear mixed models adjusted for BMI and medications showed that a 10-unit increase in AHI was associated with elevated glucose levels at night (11 pm–3 am: 0.20 mmol/L, 95 percent confidence interval [CI], 0.04–0.40), which persisted into the morning (8 am: 0.26 mmol/L, 95 percent CI, 0.08–0.4).

Moreover, REM-AHI but not non-REM-AHI was linked to increased nocturnal and morning glucose levels. AHI showed no association with either mean daytime or 24-hour glucose levels.

The present data highlight SDB as a potential risk factor for elevations in glucose at night and early in the morning among women with GDM, researchers said. Long-term prospective studies are needed to validate the findings and examine whether such glucose elevations carry a risk of adverse pregnancy and child outcomes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 3 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.